Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus CLARITIN D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus CLARITIN D 24 HOUR.
CLARITIN HIVES RELIEF REDITAB vs CLARITIN-D 24 HOUR
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Selective inverse agonist of peripheral histamine H1 receptors, inhibiting histamine release from mast cells and basophils.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
Relief of symptoms associated with seasonal and perennial allergic rhinitisTreatment of chronic idiopathic urticaria
Relief of symptoms of seasonal allergic rhinitis (e.g., sneezing, rhinorrhea, nasal congestion, pruritus)Relief of nasal congestion associated with the common cold
10 mg orally once daily
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
None Documented
None Documented
Terminal elimination half-life of loratadine is 8.4 hours (range 3–20 hours); for its active metabolite descarboethoxyloratadine, it is 24.9 hours (range 8.8–45 hours). Clinical context: Steady-state concentrations are achieved by day 5.
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Primarily metabolized by CYP3A4 to descarboethoxyloratadine; also metabolized by CYP2D6 to a lesser extent.
Loratadine: extensively metabolized by CYP3A4 and CYP2D6 to active metabolite desloratadine; pseudoephedrine: partially metabolized in liver by N-demethylation.
Primarily renal (approximately 40% as metabolites, <1% as unchanged drug) and fecal (approximately 40% as metabolites).
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Loratadine: 97–99% bound to albumin and alpha-1-acid glycoprotein. Descarboethoxyloratadine: 73–76% bound.
Loratadine: 97-99% bound to plasma proteins (mainly albumin and α1-acid glycoprotein); desloratadine: 73-76% bound.
Loratadine: approximately 120 L/kg (high, indicating extensive tissue distribution). Descarboethoxyloratadine: 704 L/kg.
Loratadine: 119 L/kg (apparent Vd/F ~1000 L). High Vd indicates extensive tissue distribution. Desloratadine: 148 L/kg (apparent Vd/F ~2500 L).
Oral bioavailability of loratadine is 40–50% due to first-pass metabolism. The orally disintegrating tablet is bioequivalent to conventional tablets.
Oral: Loratadine absolute bioavailability is ~40% due to first-pass metabolism; food increases AUC by 40% and delays Tmax. Desloratadine absolute bioavailability is ~50%.
No adjustment required. CrCl 10-50 mL/min: use with caution; CrCl <10 mL/min: contraindicated if anuria.
GFR 30-89 mL/min: no adjustment; GFR <30 mL/min or ESRD: contraindicated due to pseudoephedrine component
Child-Pugh A: no adjustment; Child-Pugh B or C: start 5 mg orally once daily.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: contraindicated due to insufficient data
6-12 years: 5 mg orally once daily; >12 years: 10 mg orally once daily. Weight-based: not typically required.
Not recommended for children under 12 years; age 12-17 years: 1 tablet orally once daily
No specific adjustment; monitor for dizziness or sedation.
Caution in patients >60 years due to increased sensitivity to pseudoephedrine (nervousness, dizziness, sleep disturbances) and higher risk of adverse effects; consider alternative therapy
None
None.
Severe hepatic impairment (dose adjustment required); renal impairment (CrCl <30 mL/min, starting dose of 10 mg every other day); use with caution in patients with history of seizures; may impair ability to drive or operate machinery.
["Cardiovascular effects: caution in hypertension, arrhythmias, ischemic heart disease","Central nervous system stimulation: may cause insomnia, dizziness, tremor","Urinary retention: caution in patients with prostatic hypertrophy","Glaucoma: may increase intraocular pressure","Use with MAOIs: hypertensive crisis risk","Diabetes: may increase blood glucose"]
Hypersensitivity to loratadine or any component of the formulation; severe hepatic impairment (Child-Pugh class C) without dose adjustment.
["Hypersensitivity to loratadine, pseudoephedrine, or any component","Severe hypertension","Severe coronary artery disease","Concurrent use or within 14 days of MAOIs","Narrow-angle glaucoma","Urinary retention","Lactation (due to pseudoephedrine)"]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice may slightly increase absorption but is clinically irrelevant. Avoid alcohol to minimize sedation risk.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) due to potential hypertensive crisis with pseudoephedrine. Grapefruit juice may increase pseudoephedrine absorption; limit intake. Avoid alcohol, which can exacerbate CNS sedation from loratadine.
FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects; no adequate human studies in pregnant women. Potential for minor malformations not established. Risk to fetus considered low based on limited data.
FDA Pregnancy Category B. Animal studies show no fetal risk; no adequate human studies in first trimester. Pseudoephedrine may cause uterine vasoconstriction; avoid in preeclampsia or reduced placental perfusion. No known teratogenicity from loratadine or pseudoephedrine in human pregnancy.
Loratadine is excreted into human breast milk in small amounts (M/P ratio approximately 1.2). Not expected to cause adverse effects in nursing infants at usual doses. Caution recommended due to lack of long-term safety data.
Loratadine: M/P ratio ~1.2; excreted in breast milk in low amounts (0.029% of maternal dose). Pseudoephedrine: M/P ratio ~3.5; excreted in milk (4-6% of maternal dose), may reduce milk production and cause irritability in infants. Use caution, especially with high doses or prolonged use.
No dose adjustment required. Pharmacokinetics of loratadine are not significantly altered in pregnancy based on limited studies. Standard adult dose of 10 mg once daily is used.
No dose adjustment typically required; pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not significant enough to require dose modification. Use lowest effective dose, avoid in severe hypertension or coronary artery disease.
Category C
Category C
Loratadine is a long-acting non-sedating antihistamine for chronic urticaria and allergic rhinitis. Onset within 1-3 hours, duration 24 hours. Avoid in severe hepatic impairment (Child-Pugh >10). No QT prolongation at therapeutic doses.
CLARITIN-D 24 HOUR combines loratadine (antihistamine) and pseudoephedrine (decongestant). Avoid in patients with severe hypertension, coronary artery disease, or MAOI use within 14 days. Monitor for insomnia, tachycardia, and urinary retention, especially in elderly males with BPH. Contraindicated in narrow-angle glaucoma.
Take once daily with or without food.Do not exceed 1 tablet daily.May cause drowsiness in rare cases; avoid driving if affected.Not for immediate relief of hives; takes up to 3 hours for effect.Stop use and consult doctor if hives persist >6 weeks or worsen.
Do not crush or chew the tablet; swallow whole with a full glass of water.Avoid taking within 4-6 hours of bedtime to prevent insomnia.Do not use with other decongestants or cold remedies containing pseudoephedrine.Discontinue and consult healthcare provider if you experience chest pain, rapid heart rate, dizziness, or difficulty urinating.